MASS Strangle Strategy

MASS (908 Devices Inc.), in the Healthcare sector, (Medical - Devices industry), listed on NASDAQ.

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.

MASS (908 Devices Inc.) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $285.1M, a beta of 0.57 versus the broader market, a 52-week range of 4.21-9.34, average daily share volume of 276K, a public-listing history dating back to 2020, approximately 246 full-time employees. These structural characteristics shape how MASS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.57 indicates MASS has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a strangle on MASS?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current MASS snapshot

As of May 15, 2026, spot at $6.97, ATM IV 120.80%, IV rank 33.64%, expected move 34.63%. The strangle on MASS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this strangle structure on MASS specifically: MASS IV at 120.80% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 34.63% (roughly $2.41 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated MASS expiries trade a higher absolute premium for lower per-day decay. Position sizing on MASS should anchor to the underlying notional of $6.97 per share and to the trader's directional view on MASS stock.

MASS strangle setup

The MASS strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With MASS near $6.97, the first option leg uses a $7.32 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed MASS chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 MASS shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$7.32	N/A
Buy 1	Put	$6.62	N/A

MASS strangle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

MASS strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on MASS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on MASS

Strangles on MASS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the MASS chain.

MASS thesis for this strangle

The market-implied 1-standard-deviation range for MASS extends from approximately $4.56 on the downside to $9.38 on the upside. A MASS long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current MASS IV rank near 33.64% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on MASS should anchor more to the directional view and the expected-move geometry. As a Healthcare name, MASS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to MASS-specific events.

MASS strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. MASS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move MASS alongside the broader basket even when MASS-specific fundamentals are unchanged. Always rebuild the position from current MASS chain quotes before placing a trade.

Frequently asked questions

What is a strangle on MASS?: A strangle on MASS is the strangle strategy applied to MASS (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With MASS stock trading near $6.97, the strikes shown on this page are snapped to the nearest listed MASS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are MASS strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the MASS strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 120.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a MASS strangle?: The breakeven for the MASS strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current MASS market-implied 1-standard-deviation expected move is approximately 34.63%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on MASS?: Strangles on MASS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the MASS chain.
How does current MASS implied volatility affect this strangle?: MASS ATM IV is at 120.80% with IV rank near 33.64%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.